Literature DB >> 2503277

Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages.

C Moreno1, J Taverne, A Mehlert, C A Bate, R J Brealey, A Meager, G A Rook, J H Playfair.   

Abstract

We show here that purified lipoarabinomannan (LAM) from Mycobacterium tuberculosis can cause the release of tumour necrosis factor (TNF) in vitro from human blood monocytes and activated mouse peritoneal macrophages, and the production of TNF in vivo in mice pretreated with Propionibacterium acnes, with a potency comparable to that of lipopolysaccharide (LPS) from Gram negative bacteria. Like LPS, LAM binds to polymyxin B. We confirmed that its activity was distinct from any contaminating LPS and was associated with the antigenic activity by affinity chromatography, using a monoclonal antibody specific for LAM. Treatment with dilute alkali greatly diminished the TNF-inducing activity, suggesting that omicron-acyl groups may be involved. When LAM was fractionated by electrophoresis on SDS-Page and blotted on nitrocellulose, most TNF-inducing capacity coincided with the bulk of the LAM, as estimated by molecular weight and antigenic activity. This modification of the Western blotting technique may be generally useful for the study of macrophage-triggering molecules. The ability of LAM to cause the release of TNF may be responsible for some of the characteristics of tuberculosis, such as fever, weight loss, raised acute phase reactants and necrosis that can be mediated by this cytokine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503277      PMCID: PMC1541837     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Non-reactive tuberculosis.

Authors:  J R O'BRIEN
Journal:  J Clin Pathol       Date:  1954-08       Impact factor: 3.411

Review 2.  Role of activated macrophages in the immunopathology of tuberculosis.

Authors:  G A Rook
Journal:  Br Med Bull       Date:  1988-07       Impact factor: 4.291

3.  Immunological activity of a 38-kilodalton protein purified from Mycobacterium tuberculosis.

Authors:  D Young; L Kent; A Rees; J Lamb; J Ivanyi
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

Review 4.  Leprosy and the leprosy bacillus: recent developments in characterization of antigens and immunology of the disease.

Authors:  H Gaylord; P J Brennan
Journal:  Annu Rev Microbiol       Date:  1987       Impact factor: 15.500

5.  Demonstration of soluble Plasmodium falciparum antigens reactive with Limulus amoebocyte lysate and polymyxin B.

Authors:  P H Jakobsen; L Baek; S Jepsen
Journal:  Parasite Immunol       Date:  1988-11       Impact factor: 2.280

6.  The role of gamma-interferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis.

Authors:  G A Rook; J Taverne; C Leveton; J Steele
Journal:  Immunology       Date:  1987-10       Impact factor: 7.397

7.  Lipoarabinomannan and lipid-free arabinomannan antigens of Mycobacterium paratuberculosis.

Authors:  E A Sugden; B S Samagh; D R Bundle; J R Duncan
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

8.  Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice.

Authors:  J L Rothstein; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

9.  Malarial parasites induce TNF production by macrophages.

Authors:  C A Bate; J Taverne; J H Playfair
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

10.  Mechanism of the anti-tumour effect of glucans and fructosans: a comparison with C. parvum.

Authors:  R Bomford; C Moreno
Journal:  Br J Cancer       Date:  1977-07       Impact factor: 7.640

View more
  61 in total

1.  An Afghan child with deep vein thrombosis.

Authors:  R Gupta; M Brueton; J Fell; H Lyall
Journal:  J R Soc Med       Date:  2003-06       Impact factor: 5.344

2.  Structural basis of capacity of lipoarabinomannan to induce secretion of tumor necrosis factor.

Authors:  D Chatterjee; A D Roberts; K Lowell; P J Brennan; I M Orme
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

Review 3.  Antigens of the Mycobacterium avium, Mycobacterium intracellulare complex.

Authors:  S L Morris
Journal:  Eur J Epidemiol       Date:  1991-07       Impact factor: 8.082

4.  Regulation of the interleukin-1 beta (IL-1 beta) gene by mycobacterial components and lipopolysaccharide is mediated by two nuclear factor-IL6 motifs.

Authors:  Y Zhang; W N Rom
Journal:  Mol Cell Biol       Date:  1993-06       Impact factor: 4.272

5.  Defective antigen presentation by Mycobacterium tuberculosis-infected monocytes.

Authors:  J Gercken; J Pryjma; M Ernst; H D Flad
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice.

Authors:  P L Dunn; R J North
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Tumor necrosis factor production in patients with leprosy.

Authors:  P F Barnes; D Chatterjee; P J Brennan; T H Rea; R L Modlin
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  Mechanisms of stimulation of interleukin-1 beta and tumor necrosis factor-alpha by Mycobacterium tuberculosis components.

Authors:  Y Zhang; M Doerfler; T C Lee; B Guillemin; W N Rom
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence.

Authors:  L B Adams; Y Fukutomi; J L Krahenbuhl
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

10.  Effect of lipoarabinomannan and mycobacteria on tumour necrosis factor production by different populations of murine macrophages.

Authors:  M G Bradbury; C Moreno
Journal:  Clin Exp Immunol       Date:  1993-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.